References

  1. Ledford, Heidi. “Cancer: The Ras renaissance.” Nature 520.7547 (2015): 278-280.
  2. Matikas, Alexios et al. “Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.” Crit Rev Oncol Hematol 110 (2017): 1-12.
  3. Ostrem, Jonathan M., Shokat, Kevan M. “Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.” Nat Rev Drug Discov 15.11 (2016): 771-785.
  4. Bos, Johannes L. “ras oncogenes in human cancer: a review.” Cancer Res 49.17 (1989): 4682-4689
  5. Simanshu, Dhirendra K. et al. “RAS proteins and their regulators in human disease.” Cell 170.1 (2017): 17-33.
  6. Mirati estimates based on epidemiology data reported in Globocan 2022 (accessed 2019) and frequencies by mutation; Europe includes EU, Russia and 10 additional European countries; RET estimate does not include thyroid cancer. Rounded to the nearest 1,000.
  7. Zehir A et al, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703-713”
  8. Campbell et al, Nature Genetics 2016 “Distinct patterns of somatic genome alterations in lung adenocarcinomas”
  9. Bailey P et al, Nature 2016 “Genomic analyses identify molecular subtypes of pancreatic cancer”
  10. Hallin J. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery, 2019.
  11. Pircher et al., Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints. Int J Mol Sci, 2017. 18(11).
  12. Akalu, Y.T., C.V. Rothlin, and S. Ghosh, TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev, 2017. 276(1): p. 165-177.
  13. Mirati Therapeutics. Data on File.
  14. Kwilas, A.R., R.N. Donahue, K.Y. Tsang, and J.W. Hodge, Immune consequences of tyrosinekinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron, 2015.